Affordable Access

Access to the full text

Docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy for patients with cervical esophageal cancer: a single-center retrospective study

  • Sakai, Makoto1
  • Sohda, Makoto1
  • Saito, Hideyuki1
  • Kuriyama, Kengo1
  • Yoshida, Tomonori1
  • Kumakura, Yuji1
  • Hara, Keigo1
  • Yokobori, Takehiko2
  • Miyazaki, Tatsuya1
  • Murata, Kazutoshi3
  • Noda, Shin-ei4
  • Nakano, Takashi3
  • Kuwano, Hiroyuki1, 5
  • Shirabe, Ken1
  • 1 Gunma University, Department of General Surgical Science, Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan , Maebashi (Japan)
  • 2 Gunma University Graduate School of Medicine, Department of Innovative Cancer Immunotherapy, Maebashi, Japan , Maebashi (Japan)
  • 3 Gunma University Graduate School of Medicine, Department of Radiation Oncology, Maebashi, Japan , Maebashi (Japan)
  • 4 International Medical Center, Saitama Medical University, Department of Radiation Oncology, Saitama, Japan , Saitama (Japan)
  • 5 Fukuoka City Hospital, Fukuoka, Japan , Fukuoka (Japan)
Published Article
Cancer Chemotherapy and Pharmacology
Publication Date
Apr 09, 2019
DOI: 10.1007/s00280-019-03835-0
Springer Nature


BackgroundTo evaluate the efficacy of docetaxel, cisplatin, and 5-fluorouracil as combination chemoradiotherapy (DCF-RT) for cervical esophageal cancer (CEC), we performed a retrospective analysis of CEC patients treated by DCF-RT at a single institution.MethodsWe conducted a single-center retrospective study. Twenty-one patients with CEC who underwent DCF-RT between 1999 and 2017 at our institute were included in this study. Chemotherapy consisted of intravenous docetaxel at 50 mg/m2 on day 1, intravenous CDDP at 60 mg/m2 on day 1, and intravenous 5-FU at 600 mg/m2 on days 1–4, repeated every 4 weeks for two cycles. Among the 21 patients, six were irradiated using three-dimensional conformal RT (3D- conformal RT) and 15 were treated using intensity-modulated RT (IMRT) consisting of 60 Gy in 30 fractions.ResultsThe median follow-up period was 49.6 months (range 4.6–97.6). The overall complete response (CR) and local CR rates were 61.9% and 81.0% for all patients, and 76.9% and 84.6% for patients without hypopharyngeal and/or thoracic esophageal invasion, respectively. The 3-year overall survival (OS), progression-free survival (PFS), and local failure-free survival (LFFS) rates were 79.6, 52.4, and 74.7%, respectively. Grade 3–4 leucopenia developed in 12 patients (70.6%), neutropenia developed in 13 patients (81.2%), and mucositis developed in 2 patients (9.5%). There were no treatment-related deaths.ConclusionsThe 3-year OS and LFFS of patients who underwent DCF-RT were higher than those in the previous studies. Although the high rate of myelosuppression requires careful management, DCF-RT is a safe and effective modality for CEC.

Report this publication


Seen <100 times